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Abstract: Background: Squamous intraepithelial lesions/cervical intraepithelial neoplasias 
(SIL/CIN) are high-risk human papilloma virus (hrHPV)-related lesions which are considered as 
high grade (HSIL/CIN2-3) or low grade (LSIL/CIN1) lesions according to their risk of progression 
to cervical cancer (CC). Most HSIL/CIN2-3 are considered as transforming hrHPV infections, so 
truly CC precursors, although some clear spontaneously. hrHPV testing has a high sensitivity for 
the detection of HSIL/CIN2-3 but a relatively low specificity for identifying transforming lesions. 
We aimed to determine whether the combination of CADM1, MAL and miR124 promoter 
methylation status assessed in histological samples can be used as a biomarker in the identification 
of transforming HSIL/CIN lesions. Design: 131 cervical biopsies, including 8 cases with no lesion 
and a negative hrHPV test result (control group), 19 low-grade (L)SIL/CIN1, 30 HSIL/CIN2, 60 
HSIL/CIN3, and 14 CC were prospectively collected. hrHPV was detected and genotyped using the 
polymerase chain reaction (PCR)-based technique SPF10 HPV LIPA. A multiplex quantitative 
methylation-specific PCR (qMSP) was used to identify the methylation status of the CADM1, MAL, 
and miR124 promoter genes. Results: Significantly higher methylation levels of CADM1, MAL and 
miR-124 were found in HSIL/CIN2-3 and CC compared with normal and LSIL lesions. DNA 
methylation of at least one gene was detected in 12.5% (1/8) of normal samples, 31.5% (6/19) of 
LSIL/CIN1, 83.3% (25/30) of HSIL/CIN2, 81.6% (49/60) of HSIL/CIN3 and 100% (14/14) of CC (p < 
0.001). The sensitivity and specificity for HSIL/CIN2-3 and CC of having at least one methylated 
gene were 84.6% and 74.0%, respectively. The sensitivity and specificity of the combination of at 
least one methylated gene and a positive hrHPV test were 80.7% and 85.1% for HSIL/CIN2-3 and 
CC, respectively. Conclusions: The methylation rate of CADM1, MAL and miR124 increases with 
the severity of the lesion. Further research is warranted to evaluate the usefulness of these 
biomarkers for the identification of transforming HSIL/CIN. 
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Virtually all cervical cancers (CC) result from persistent infection by high-risk human papilloma 
virus (hrHPV) and are preceded by precursor lesions referred to as squamous intraepithelial lesions or 
cervical intraepithelial neoplasia (SIL/CIN) [1]. These precursor lesions are divided into “productive” 
and “transforming” lesions according to their risk of progression to CC [2]. From the clinical 
perspective, only the latter lesions should be considered as true premalignant abnormalities requiring 
exhaustive colposcopy and treatment to prevent CC. Most low-grade SIL/CIN grade 1 (LSIL/CIN1) are 
considered to represent productive lesions, whereas most HSIL/CIN grade 2 and 3 (HSIL/CIN2-3) are 
classified as transforming lesions. Nevertheless, HSIL/CIN2-3, and particularly HSIL/CIN2, is believed 
to be a heterogeneous disease, as suggested by the fact that some molecular features common to almost 
all CC are found in only a subset of HSIL/CIN2-3 [3–6], which indicates that not all these lesions have 
the same risk of progression to CC, and that some are productive infections. Similarly, a small 
proportion of LSIL may represent an early phase of a transforming lesion. 
hrHPV tests have a high sensitivity for the detection of cervical premalignant lesions and CC. 
However, hrHPV tests have shown a low specificity and positive predictive value (PPV), as all 
HSIL/CIN2-3 as well as most productive LSIL/CIN1 lesions are positive for hrHPV independently of 
their risk of progression [7]. Thus, there is a need for biomarkers able to specifically identify the 
transforming HSIL/CIN2-3 lesions requiring treatment and to exclude LSIL/CIN1 and ideally the 
subset of HSIL/CIN2-3 thought to be productive lesions with a low risk of progression to CC, in order 
to reduce the adverse events and costs associated with unnecessary treatments. 
Hypermethylation of CpG islands in the promoter regions of tumor suppressor genes leads to 
silencing of the gene and is an essential step in the development of many cancers, including CC [8]. 
Hypermethylation of promoter regions in certain genes has also been suggested as a molecular 
alteration appearing in transforming HSIL/CIN2-3 lesions at high risk of progression to CC [9–14]. 
Recent studies have shown that the combination of methylation-mediated silencing of CADM1 (cell 
adhesion molecule 1) and MAL (T-lymphocyte maturation-associated protein) promoter genes in 
cervical scrapes seems to be related to the duration of hrHPV infection and the severity of the SIL/CIN 
lesion [10,15]. In addition, methylation of CpG-rich regulatory sequences can result in a down-
regulation of micro RNAs (miR) and, interestingly, down-regulation of certain miR, such as miR124, 
has been linked to increased promoter methylation of the CADM1 and MAL genes [16]. 
In the present study, we analyzed CADM1, MAL and miR124 methylation status in addition to 
hrHPV testing and genotyping in a series of cervical biopsies from women referred to colposcopy 
due to an abnormal screening test. The aim of the study was to determine if these biomarkers might 
be related to lesion severity and might, therefore, be useful in the characterization of transforming 
HSIL/CIN lesions in a referral population. 
2. Results 
One hundred forty-six histological samples were eligible for the study. Fifteen (10.27%) were 
excluded due to low DNA quality for methylation analysis. Of the remaining 131 samples considered 
as adequate for analysis, eight were negative (control group); 19 were LSIL/CIN1, 30 were 
HSIL/CIN2, 60 were HSIL/CIN3, and 14 were CC. The median age of the patients in each diagnostic 
category was 36.1 years in the control group (range 21–50 years); 36.8 years in the LSIL/ CIN1 group 
(range 17–60 years), 34.0 years in the HSIL/CIN2 (range 22–45 years), 36.0 years in the HSIL/CIN3 
(range 23–52 years), and 53.0 years in the CC group (range 27–76 years). Women with CC were 
significantly older than those in the other groups (p < 0.001). 
2.1. Methylation Status 
Figure 1 shows the ∆∆Cq levels of CADM1, MAL, and miR124 in the different groups. The 
methylation levels of CADM1, MAL and miR-124 were significantly lower in LSIL samples compared 
with HSIL/CIN3 and CC. No significant differences were found in methylation levels between negative 
and LSIL samples for any of the biomarkers. Neither were significant differences found in the 
methylation levels between HSIL/CIN3 and CC samples. The methylation levels of CADM1 were 
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significantly lower in HSIL/CIN2 compared with HSIL/CIN3 and CC (p = 0.008 and 0.008, respectively). 










Figure 1. Boxplots of the levels of CADM1 (A), MAL (B), and miR124 (C) expressed as 10log-
transformed values, in women with normal, low-grade squamous intraepithelial lesion/cervical 
intraepithelial neoplasia grade 1 (LSIL/CIN1), high-grade squamous intraepithelial lesion/cervical 
intraepithelial neoplasia grades 2 (HSIL/CIN2), HSIL/CIN3, and cervical cancer (CC). The black line 
within the box represents the median; the whiskers represent the minimum and maximum values 
that lie within 1.5 interquartile ranges from the end of the box. Values outside this range are 
represented by black dots. * CADM1 showed lower levels of methylation in LSIL/CIN1 samples 
compared with HSIL/CIN3 and CC (p = 0.006 and p = 0.031, respectively) and lower levels of 
methylation in HSIL/CIN2 samples compared with HSIL/CIN3 and CC (p = 0.008 and p = 0.008, 
respectively). Methylation levels of the MAL promoter gene were lower in negative and LSIL/CIN1 
samples compared with HSIL/CIN3 (p = 0.001 and p = 0.003, respectively) and CC (p = 0.003 and p = 
0.003, respectively). MAL also showed lower methylation levels in HSIL/CIN2 samples compared 
with CC (p = 0.029). miR124 showed lower levels of expression in negative and LSIL/CIN1 samples 
compared with HSIL/CIN2 (p = 0.001 and p = 0.003, respectively), HSIL/CIN3 (p < 0.001 and p< 0.001, 
respectively) or CC (p = 0.019 and p = 0.024, respectively). 
Table 1 shows the methylation status of the MAL, CADM1, and miR-124 promoter genes in the 
different diagnostic groups as well as the positivity rate for the combination of the three biomarkers. 
The methylation rates significantly increased with the severity of the lesion for all of the genes. None 
of the samples from the control group showed methylation of the CADM1 and MAL genes and only 
one sample showed methylation of miR124. All CC and more than 80% of the HSIL/CIN2-3 lesions 
showed at least one methylated gene. 
Table 2 shows the sensitivity, specificity, PPV, and NPV of the methylation of the different 
promoter genes for the detection of HSIL/CIN2+ and HSIL/CIN3+ regardless of HPV status. miR124 
was the most sensitive marker for the detection of HSIL/CIN2+ and HSIL/CIN3+, whereas CADM1 
was the most specific. The sensitivity and specificity of having at least one methylated gene for 
HSIL/CIN2+ was 84.6% and 74.0%, respectively, and 85.1%, and 43.8% for HSIL/CIN3+. When the 
three genes were methylated, the specificity for HSIL/CIN2+ was 100%. 
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Table 1. Positivity rates for MAL, CADM1, and miR-124 methylation and combinations of at least 
one, two, or three methylated biomarkers in the different diagnostic groups. LSIL/CIN1: Low-grade 
squamous intraepithelial lesion/cervical intraepithelial neoplasia grade 1; HSIL/CIN2: High-grade 
squamous intraepithelial lesion/cervical intraepithelial neoplasia grade 2; HSIL/CIN3: High-grade 
squamous intraepithelial lesion/cervical intraepithelial neoplasia grade 3; CC: Cervical cancer. 
Biomarker 
Negative (n = 8) 
LSIL/CIN1 (n = 
19) 
HSIL/CIN2 (n = 
30) 
HSIL/CIN3 (n = 
60) CC (n = 14) p 
n (%) n (%) n (%) n (%) n (%) 
CADM1 0 (0.0) 2 (10.5) 2 (6.6) 31 (51.6) 8 (57.4) <0.001 
MAL 0 (0.0) 2 (10.5) 17 (56.6) 36 (60.0) 13 (92.8) <0.001 
miR124 1 (12.5) 3 (15.7) 20 (66.6) 41 (68.3) 11 (78.5) <0.001 
At least one methylated gene  1 (12.5) 6 (31.5) 25 (83.3) 49 (81.6) 14 (100) <0.001 
At least two methylated genes  0 (0.0) 1 (5.2) 13 (43.3) 36 (60.0) 12 (85.7) <0.001 
Three methylated genes  0 (0.0) 0 (0.0) 1 (3.3) 23 (38.3) 6 (42.8) <0.001 
Table 2. Sensitivity, specificity, positive, and negative predictive values (PPV and NPV, respectively) 
of the methylation of MAL, CADM1, or miR-124, and of at least one, two, or the three genes for 
HSIL/CIN2+ and HSIL/CIN3+. HSIL/CIN2+ includes high-grade squamous intraepithelial 
lesion/cervical intraepithelial neoplasia grade 2 (HSIL/CIN2), HSIL/CIN3 and cervical cancer (CC). 
HSIL/CIN3+ includes HSIL/CIN3 and CC. 
 Sensitivity Specificity PPV PNV 
HSIL/CIN2+      
CADM1 39.4 92.5 95.3 28.4 
MAL 63.4 92.5 97.0 39.0 
miR124 69.2 85.1 94.7 41.8 
At least one methylated gene  84.6 74.0 92.6 55.0 
Two methylated genes  58.6 96.2 98.3 37.6 
Three methylated genes  28.8 100.0 100.0 26.7 
HSIL/CIN3+      
CADM1 52.7 92.9 90.6 60.2 
MAL 66.2 56.7 72.0 60.3 
miR124 70.2 57.8 68.4 60.0 
At least one methylated gene  85.1 43.8 66.3 69.4 
Two methylated genes  64.8 75.4 77.4 62.3 
Three methylated genes  39.1 98.2 96.6 55.4 
2.2. Correlation between Methylation Status and the Percentage of the Biopsy Involved by the Lesion 
The mean area of the biopsies was 7.9 mm2 (SD 5.5 mm2). No differences were found between 
the different diagnostic groups (p = 0.395). The mean percentage of the total biopsy area occupied by 
the squamous epithelium was 50.2mm2 (SD 31.9 mm2), with no differences observed between the 
diagnostic groups (51.1% for the normal biopsies, 56.5% for the LSIL/CIN1, 49.9% for the HSIL/CIN2, 
46.7% for the HSIL/CIN3 and 83.6% for the CC; p = 0.393). The percentage of the squamous epithelium 
involved by the lesion was 58.9% for the LSIL/CIN1, 77.5% for the HSIL/CIN2, 69.8% for the 
HSIL/CIN3, and 90.2% for the CC; p = 0.423). No correlation has been found between the percentage 
of squamous epithelium involved by the lesion and the methylation results. 
2.3. hrHPV Testing and Genotyping and p16 Immunostaining 
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Within the group of patients with LSIL/CIN1, five out of the 19 (26.3%) samples were positive 
for hrHPV16/18, nine (9/19; 47.4%) were positive for hrHPV non16-18, four (4/19; 21.1%) were positive 
for low-risk HPV, and one (5.2%) was negative. All the patients with HSIL/CIN2 were positive for 
hrHPV, with 50% (15/30) being positive for hrHPV16/18, and 50% (15/30) for hrHPV non16-18. 
Similarly, all the patients with HSIL/CIN3 were positive for hrHPV, 60% (36/60) being positive for 
hrHPV16/18 and 40% (24/60) for hrHPV non16-18. Among the group of patients with CC, 78.6% 
(11/14) were positive for hrHPV16/18, 7.1% (1/14) for hrHPV non16-18, and 14.3% (2/14) were 
negative for HPV. hrHPV16/18 genotyping showed a sensitivity and specificity for HSIL/CIN2+ of 
50.1% and 81.5%, respectively. 
p16 immunostaining was positive in 78.9% (15/19) patients with LSIL/CIN1 and in 100% of the 
HSIL/CIN2, HSIL/CIN3 and CC biopsies. 
2.4. Combinations of Biomarkers 
Figure 2 shows the results of the methylation status of CADM1, MAL, and miR124, p16 
immunostaining and HPV testing and genotyping for each case in the different groups included in 
the study.  
Table 3 shows the correlation between HPV genotyping and methylation status in the different 
diagnostic categories. There was no statistically significant correlation between methylation status 
and HPV genotyping for any of the groups. 
Table 3. Correlation between HPV genotyping and methylation of at least one biomarker in the different 
diagnostic groups. HPV: Human papillomavirus; lrHPV: Low-risk HPV; LSIL/CIN1: Low-grade 
squamous intraepithelial lesion/cervical intraepithelial neoplasia grade 1; HSIL/CIN2: High-grade 
squamous intraepithelial lesion/cervical intraepithelial neoplasia grade 2; HSIL/CIN3: High-grade 
squamous intraepithelial lesion/cervical intraepithelial neoplasia grade 3; CC: Cervical cancer. 
Histological 
Diagnosis Methylation status 
HPV Genotyping 
Negative/lrHPV HPV No 16/18 HPV16/18 
p 
n (%) n (%) n (%) 
Negative        - 
 Positive 1 (100.0) - (-) - (-)  
 Negative 7 (100.0) - (-) - (-)  
LSIL/CIN1        0.707 
 Positive 2 (33.3) 2 (33.3) 2 (33.3)  
 Negative 3 (23.1) 7 (53.8) 3 (23.1)  
HSIL/CIN2        1 
 Positive 0 (0.0) 12 (48.0) 13 (52.0)  
 Negative 0 (0.0) 3 (60.0) 2 (40.0)  
HSIL/CIN3        0.500 
 Positive 0 (0.0) 21 (42.9) 28 (57.1)  
 Negative 0 (0.0) 3 (27.3) 8 (72.7)  
CC        - 
 Positive 2 (14.3) 1 (7.1) 11 (78.6)  
 Negative 0 (0.0) 0 (0.0) 0 (0.0)  
The combination of at least one methylated gene and positivity for hrHPV reached a sensitivity 
of 80.7% and a specificity of 85.1% for HSIL/CIN2+, and the combination of at least one methylated 
gene and HPV16/18 genotyping showed a sensitivity of 43.3% and a specificity of 92.6%. 
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Figure 2. Results of the methylation status of CADM1, MAL, and miR124, p16 immunostaining and HPV testing and genotyping for each case in the different 
groups included in the study. 
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3. Discussion 
In this study, we determined the value of methylation analysis for CADM1, MAL, and miR124 
alone, in combination and in association with hrHPV genotyping for the detection of transforming 
HSIL/CIN in a number of well-characterized cervical biopsies. In keeping with previous reports, in 
the present study, methylation of CADM1, MAL, and miR124 increased in parallel with the severity 
of the cervical lesion [16,17]. Interestingly, the combination of at least one methylated gene and 
positivity for hrHPV achieved a sensitivity of 80.7% and a specificity of 85.1% for the detection of 
HSIL/CIN2+. 
Methylation of CADM1, MAL, and miR124 has been related to the severity and duration of 
cervical disease [15]. Four studies have recently shown that altered expression of several miRs 
represents an early event in hrHPV-induced carcinogenesis that is already detectable in SIL/CIN 
lesions [18,19]. In contrast, the weighted mean methylation frequencies for CADM1 and MAL were 
highest in transforming CIN lesions [11,20]. Thus, methylation analyses of CADM1, MAL, and 
miR124 seem to be able to distinguish hrHPV-positive patients with transforming lesions at short-
term risk of progression from women with clinically irrelevant infections [11,15,16]. We do not have 
follow-up data from the patients included in the study, and consequently, we cannot estimate the 
specific risk of transformation. Nevertheless, our results are in keeping with previous data showing 
that the methylation status of HSIL/CIN3 is similar to that of CC, meaning that most of them should 
be considered as truly transforming lesions. In contrast, the methylation status of HSIL/CIN2 shows 
a dissociated pattern, resembling LSIL/CIN1 for CADM1, but more similar to HSIL/CIN3 and CC for 
miR124 and MAL, suggesting that HSIL/CIN2 represents probably a heterogeneous group, with 
some lesions having less risk of progression than HSIL/CIN3. It has also been suggested that 
HSIL/CIN3 is also a heterogeneous disease, both in terms of the chromosomal aberrations detected 
and in terms of clinical behavior [10]. In our series, the methylation pattern of HSIL/CIN3 was similar 
to CC in all the genes analyzed, and although some of the HSIL/CIN3 lesions showed a different 
methylation pattern, the lack of follow-up data did not allow adequate correlation between 
methylation patterns and clinical outcomes. 
The present study analyzed methylation patterns in histological samples, showing that the result 
of methylation status is indisputably related to the sample evaluated. The analysis of these 
biomarkers in HPV-positive women in the present series of biopsies showed a very good diagnostic 
accuracy for HSIL/CIN2+ (sensitivity and specificity of 84.6% and 74.0%, respectively), which is 
consistent with current evidence in cytology [11]. We did not test the methylation status in the 
cytological samples, which would have provided some insight into the possible usefulness of 
methylation tests in the CC screening. However, a previous study showed that the methylation status 
of cervical scrapes was highly representative of that of the worst lesion, particularly in the case of 
HSIL/CIN3 or CC [11]. 
In the present series, the prevalence of HPV16 and/or 18 increased with the presence of 
histological abnormalities. These results are similar to previous reports showing that HPV16 and 18 
are more frequently associated with transforming infection [21]. In line with previous evidence, 
HPV16/18 genotyping showed a high specificity (81.5%), which increased to more than 90% when 
combined with the methylation of at least one biomarker [18]. These results suggest that women with 
HPV16 and/or 18 infection and methylation of at least one gene should be immediately referred to 
colposcopy and closely followed in case of negative findings. 
The lower anogenital squamous terminology (LAST) standardization project for HPV-associated 
lesions specifically recommends the use of p16 immunostaining as an adjunct to morphologic 
assessment of cervical biopsies to increase the sensitivity of HSIL/CIN2+ detection [22]. We used the 
LAST criteria, and in this study, p16 was negative in all the negative samples and positive in all the 
HSIL/CIN2-3 lesions. Although controversial results have been published, some studies have 
suggested that in LSIL/CIN1, p16 immunostaining could have prognostic value [7,23,24]. However, 
in the present series, no relation was found between p16 immunostaining and the methylation 
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pattern. Thus, our results are in keeping with those of a previous study by our group showing a low 
value of p16 IHC staining as a marker of progression of LSIL/CIN1 in clinical practice [22]. 
This study has some limitations. First, changes in the methylation pattern due to the presence of 
hrHPV in samples without cellular dysplasia were not evaluated. Negative biopsy samples positive for 
hrHPV were not included in the study, since this category might represent a heterogeneous group 
including hrHPV infection with no lesions and hrHPV infection with existing, but underdiagnosed, 
SIL/CIN. Second, the methylation status was evaluated on DNA extracted from the total biopsy and 
not selectively on the dysplastic cells. However, no correlation was found between the percentage of 
squamous epithelium involved by the lesion and the methylation results, which indicates a limited 
potential effect of the different fraction of dysplastic/neoplastic cells in the analysis. Finally, no follow-
up data were available, and consequently, the possible relation between methylation and the risk of 
progression to HSIL/CIN2-3 could not be assessed. Further studies including follow-up data are 
warranted in order to confirm the relationship between methylation status and the risk of progression. 
In conclusion, our study confirms that in a series of well-characterized histological cervical 
samples, the methylation of CADM1, MAL and miR124 increases with the severity of the lesion, and 
that the combination of at least one positive biomarker and positivity for hrHPV achieved a 
sensitivity of 80.7% and a specificity of 85.1% for the diagnosis of HSIL/CIN2-3. Further research 
including follow-up data is warranted to evaluate the usefulness of these biomarkers for the 
identification of truly transforming HSIL/CIN. 
4. Materials and Methods 
4.1. Study Design and Case Selection 
This prospective study was approved by the Institutional Ethical Review Board (HCB/2016/0672, 
approved on June 2016). All women signed informed consent for inclusion in the study. All patients 
referred to the Colposcopy Clinic of the Oncological Gynecology Unit of the Hospital Clinic of 
Barcelona from January 2013–December 2015 were considered eligible for the study. Referral to 
colposcopy was based on a Pap test result of atypical squamous cell (ASC), with positive hrHPV 
testing, or atypical glandular cells (AGC), LSIL, HSIL, or CC within 6 months before admission. Of 
these patients, we selected women who fulfilled the following inclusion criteria: (1) Cervical sample, 
taken at the referral visit, adequate for Pap-test and hrHPV testing and genotyping; (2) 
colposcopically directed biopsy and/or endocervical curettage taken concurrently, allowing the study 
of methylation status and p16 immunohistochemical (IHC) staining in the biopsy specimen; and (3) 
concordant results between the cervical cytology result and the histological/p16 IHC diagnosis. The 
following were considered as criteria for exclusion: (1) Previous history of CC, (2) treatment for 
HSIL/CIN2-3 performed within the previous 3 years; (3) immunosuppression, (4) pregnancy, and (5) 
low DNA quality isolated for methylation analysis. 
The study included five diagnostic groups: (1) Negative for intraepithelial lesion (control group) 
including women with a negative Pap test, a negative biopsy with negative p16 IHC staining, and a 
negative hrHPV test result; (2) LSIL/CIN1 including women with a Pap test result of LSIL and a 
biopsy showing LSIL/CIN1, independently of the p16 IHC staining results; (3) HSIL/CIN2 group 
including patients with a Pap test result of HSIL and a biopsy confirming HSIL/CIN2, including 
positive p16 IHC staining; (4) HSIL/CIN3 including patients with a Pap test result of HSIL and a 
biopsy confirming HSIL/CIN3 with positive p16 IHC staining; and (5) CC group including patients 
with Pap test result of HSIL or CC and a biopsy confirming CC, independently of the result of the 
p16 IHC staining. 
4.2. Patient Management 
At the initial visit in the colposcopy clinic, all women underwent cervical sampling using a 
cytobrush, which was transferred to PreservCyt solution (Hologic, Marlborough, MA, USA). The first 
part of the sample was used for ThinPrep liquid-based cytology. The residual material was used for 
hrHPV testing. 
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Colposcopy was performed in all patients using an Olympus Evis Exera II CV-180 colposcope 
(Olympus, Barcelona, Spain) after preparing the cervix with 5% acetic acid. Colposcopy findings were 
described using the criteria of the International Federation for Cervical Pathology and Colposcopy 
(IFCPC) [25]. In all patients showing an abnormal area in the colposcopic examination, a directed 
biopsy was performed. In addition, if the transformation zone was not completely visible, 
endocervical curettage using a Kervokian curette was also performed. A random biopsy was taken 
from the transformation zone in all the women with a completely visible transformation zone with 
no colposcopy abnormalities. 
4.3. Liquid-Based Cytology and Histological Diagnosis 
Thin-layer cytology slides were prepared using the Thinprep T2000 slide processor (Hologic, 
Mississauga, ON, Canada) and stained using the Papanicolaou method. Cytology slides were 
evaluated by a cytotechnologist and confirmed by an expert pathologist using the revised Bethesda 
nomenclature [26]. 
Biopsy specimens were fixed in 10% buffered neutral formalin and paraffin-embedded. Three µm 
sections were stained with hematoxylin and eosin (H&E), examined by a gynecological pathologist and 
classified as negative, LSIL/CIN1, HSIL/CIN2, and HSIL/CIN3, or CC. The histological diagnoses were 
established using morphologic criteria based on the H&E stained sections and the results of the IHC 
staining for p16, being blinded to knowledge of HPV status or cytology results. 
4.4. Immunohistochemical Detection of p16 
All histological samples were stained with p16 (CINtec Histology kit, cloneE6H4; Roche-Mtm-
Laboratories, Heidelberg, Germany) following the manufacturer’s protocol. Briefly, IHC was 
performed with the Autostainer Link 48 automated system (Dako Co, Carpinteria, CA, USA) using 
the EnVision system (Dako Co, CA, USA). Each series included a positive control consisting of a 
HSIL/CIN3. Cases with a complete absence of p16 staining were classified as negative. The 
immunostaining was scored as focal when either discontinuous staining of isolated basal cells or any 
type of staining of superficial and/or suprabasal layers was detected. Diffuse staining was defined as 
continuous block staining of the basal and suprabasal cells in an area, with both nuclear and 
cytoplasmic reaction, independently of whether the superficial cells of the squamous epithelium were 
stained or not [27]. Only diffuse staining was considered a positive reaction. The histological 
diagnosis of negative for intraepithelial lesion required a negative result for p16 IHC staining. A p16 
positive staining was required for the diagnosis of HSIL/CIN2 and HSIL/CIN3. The diagnoses of LSIL 
and CC were independent of the results of the p16 IHC. 
4.5. Nucleic-Acid Isolation from Histological Samples 
DNA extraction was performed on formalin-fixed paraffin-embedded histological tissue from 
colposcopically-directed biopsies or endocervical curettages. The samples were serially sectioned on 
a microtome. The first and last sections were stained with H&E for histological confirmation of the 
diagnosis. In-between sections were collected in RNAase-free reaction tubes for DNA isolation 
(sandwich cutting technique). 
Sectioning and sample preparation were carried out with the highest safety measures to avoid 
contamination and cross-contamination. Paraffin blocks lacking tissue were cut in between the 
patient samples as controls to ensure the absence of contamination. None of these control samples 
were positive in the HPV PCR assay, indicating adequate avoidance of contamination. 
DNA was extracted by overnight incubation in 20 µL of proteinase K solution (1 mg/mL) at 70 
°C. Subsequently, proteinase K was heat-inactivated by incubation of the sections at 95 °C for 10 min, 
and samples were spun down and cooled down at −20 °C for 1–2 min. DNA was isolated using a 
commercially available kit (QIAamp DNA minikit; Qiagen, Hilden, Germany), according to the 
manufacturer’s instructions, and 10 µL of isolated DNA was used for PCR amplification. DNA yields 
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were quantified spectrophotometrically using the NanoDrop ND–1000 (Thermo Scientific 
NanoDrop, Wilmington, DE, USA). 
4.6. hrHPV Genotyping of Histological Samples 
For hrHPV detection, DNA isolated from cervical biopsies was used directly for amplification by 
broad-spectrum primers that amplify a 65 bp region of the L1 gene. The amplification products were 
detected by the HPV SPF10 PCR DNA enzyme immunoassay (DEIA) system (Labo Bio-medical 
Products, Rijswijk, the Netherlands), which detects at least 54 different HPV genotypes. DEIA-positive 
SPF10 amplimers were used to identify the HPV genotype by reverse hybridization on a line probe 
assay (SPF10 HPV LIPA version 1, Labo Bio-medical Products B.V., Rijswijk, The Netherlands), which 
detects 25 HPV genotypes (6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 
and 74). Each run contained negative and internal and external positive controls to monitor for the 
efficiency of DNA isolation, PCR amplification, hybridization, and genotyping procedures. Based on 
epidemiological analyses, 15 of these HPV types were regarded as high risk (16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 68, 53, 66), and the others were classified as low risk (6, 11, 34, 40, 42, 43, 44, 54, 70, 74). 
4.7. Bisulfite Treatment and Quantitative Methylation Specific PCR of Histological Samples 
Bisulfite treatment was performed using 250 ng of genomic DNA with the EZ DNA Methylation 
KitTM (Zymo Research, Orange, CA, USA) as described elsewhere [16]. The bisulfite conversion 
protocol described for the cervical scrapes was adapted to the biopsies with an additional 
pretreatment incubation for 10 min at 95 °C, and denaturation was performed at 95 °C for 20 min. 
After bisulfite treatment, methylation of the promoter regions of the cellular genes CADM1-m18, 
MAL-m1, and hsa-miR-124-2 was tested using the prototype PreCursor-M kit (Self-Screen BV, 
Amsterdam, The Netherlands). This is a quantitative multiplex methylation-specific PCR (qMSP), 
based on the TaqMan technology. Samples were run in single, separate reactions on an ABI 7500 Fast 
Real-time PCR system (Applied Biosystems, CA, USA) following the manufacturer’s instructions. In 
addition, a methylation-independent β-actin was included in the kit as a sample reference to 
determine the total amount of converted human DNA present in the reaction. To assure sample 
quality, samples with Cq-values for β-actin >32 were considered of poor DNA quality (invalid) and 
excluded from the analysis. 
4.8. Evaluation of the Percentage of the Biopsy Involved by the Lesion 
In order to evaluate the potential different fraction of dysplastic/neoplastic cells in the samples 
analyzed, the percentage of the biopsy involved by the lesion was evaluated in all cases. The 
morphometric evaluation was performed by scanning all H&E stained slides with a whole slide 
scanner Ventana iScan HT (Roche Diagnostics, Sant Cugat, Spain) at a magnification of 20×. The high-
resolution digital images of the tissue sections were measured using the Virtuoso viewer (Roche, Sant 
Cugat, Spain), which includes measuring tools. The total area of the biopsy, the total area occupied 
by squamous epithelium, and the area involved by the dysplastic epithelium were measured in each 
biopsy. 
4.9. Statistical Methods 
Categorical variables are presented as absolute number and percentages and compared using 
the χ2 or Fisher exact test. Continuous variables are presented as mean and standard deviation (SD) 
and were compared using the analysis of variance test. The quantification cycle (Cq-value) was 
determined for each target (CADM1, MAL, and miR124) using the ∆∆Cq method [16]. This method 
shows the relative difference between each marker and β-actin in a sample compared with the 
internal calibrator (Calibrator PreCursor-M kit Self-screen B.V, molecular assays, Amsterdam, The 
Netherlands) according to the manufacturer’s recommendations. 
For calculations of methylation status, a sample was scored as methylation-positive for a specific 
target when the target gene/β-actin ratio was above a fixed calculated threshold value of the 
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respective target. For each gene, the threshold was the upper limit of the 99% confidence interval (CI) 
of the mean ratio of all histologically normal samples. Overall, a sample was considered to be 
methylation-positive when at least one target was above its threshold. The frequencies of CADM1, 
MAL, and miR124 methylation positive cervical biopsies in relation to their histological diagnosis 
were calculated. The 95% CIs were determined for each proportion of methylated samples. The 
proportions of overall methylation-positive samples, HPV genotyping, and p16 immunostaining per 
histological diagnosis were compared using the Mann-Whitney U test. p values less than 0.05 were 
considered significant. The efficacy of gene methylation for the diagnosis of HSIL/CIN2+ was 
evaluated as sensitivity and specificity. 
The sensitivity and specificity and positive and negative predictive values (PPV and NPV, 
respectively) were calculated for the combination of CADM1, MAL, and miR124 promoter 
methylation status and HPV genotyping. The endpoints were the histological diagnosis of 
HSIL/CIN2+ and HSIL/CIN3+. Calculations were performed using SPSS version 22.0 software (SPSS, 
Inc., Chicago, IL, USA). 
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